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Abstract
Background: The p38a Mitogen-Activated Protein Kinase (MAPK) regulates stress- and inflammation-induced cellular
responses. Factors implicated in the development of atherosclerosis including modified low-density lipoprotein (LDL),
cytokines and even shear stress induce p38 activation in endothelial cells and macrophages, which may be important for
plaque formation. This study investigates the effects of endothelial- and macrophage-specific deficiency of p38a in
atherosclerosis development, in Apolipoprotein E deficient (ApoE
2/2) mice.
Methodology/Principal Findings: ApoE
2/2 mice with macrophage or endothelial cell-specific p38a deficiency were fed a
high cholesterol diet (HCD) for 10 weeks and atherosclerosis development was assessed by histological and molecular
methods. Surprisingly, although p38a-deficiency strongly attenuated oxidized LDL-induced expression of molecules
responsible for monocyte recruitment in endothelial cell cultures in vitro, endothelial-specific p38a ablation in vivo did not
affect atherosclerosis development. Similarly, macrophage specific deletion of p38a did not affect atherosclerotic plaque
development in ApoE
2/2 mice.
Conclusions: Although previous studies implicated p38a signaling in atherosclerosis, our in vivo experiments suggest that
p38a function in endothelial cells and macrophages does not play an important role in atherosclerotic plaque formation in
ApoE deficient mice.
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Introduction
Atherosclerosis is the primary underlying cause of cardiovascu-
lar disease and the major cause of mortality in the western world
today [1], [2]. Originally considered a primarily metabolic
disorder, atherosclerosis is now recognised as a complex disease
with a strong inflammatory component [3]. Upon exposure to
oxidized lipids, vascular endothelial cells are activated to express
chemotactic factors and adhesion molecules that are crucial for the
recruitment of monocytes. The recruited monocytes migrate into
the sub-endothelial space and differentiate into macrophages that
phagocytose lipids to become ‘foam cells’. Accumulation of foam
cells beneath the endothelium, accompanied by the infiltration of
T cells, leads to the formation of the ‘fatty streak’, which can later
on progress into advanced atherosclerotic plaques and their
complications [4]. Foam cells eventually die by apoptosis within
the lesions and their clearance by other phagocytes is important to
prevent their secondary necrosis and the formation of a necrotic
core [5]. The mechanisms that control the recruitment, retention
and cell survival, as well as the clearance of apoptotic foam cells
within the lesions, are crucial for the pathogenesis of atheroscle-
rosis. Pro-inflammatory signalling pathways that are activated
downstream of innate immune and cytokine receptors, including
the NF-kB and Mitogen-Activated Protein Kinase (MAPK)
cascades, control immune, inflammatory and cell death responses
and have been implicated in the pathogenesis of atherosclerosis
[6], [7], [8].
The p38 MAPK pathway is crucial for a wide range of biological
processes, including cell cycle, cell differentiation and apoptosis and
theexpressionofinflammatorycytokinesandchemokines[9].p38a,
the most physiologically relevant isoform of p38 involved in
inflammatory responses [10], [11], has been implicated in the
development and progression of atherosclerosis. Various roles have
been attributed to this kinase with respect to atherogenesis,
including the regulation of scavenger receptor expression and
oxidized low-density lipoprotein (oxLDL) uptake by macrophages
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21055[12], control of the expression of the monocytic chemokine receptor
CXCR2 that is induced in response to oxLDL [13] and the
migration, proliferation [14], [15] permeability [16], apoptosis [17]
and adhesion molecule expression (e.g. VCAM1)[18] of endothelial
cells. Finally, p38a is critical for the production of multiple pro-
inflammatory cytokines like tumor necrosis factor (TNF) and
interleukins IL-1b, IL-6 and IL-8 in most of the cell types that
participate in atherosclerosis development [18], [19], [20]. Thus,
p38a has been suggested to havea crucial role inthepathogenesisof
atherosclerosis by acting in cells that play a crucial role in
atherogenesis, like endothelial cells, smooth muscle cells and
macrophages.
Here, we used conditional gene targeting in mice to address in
vivo, for the first time, the endothelial cell-specific function of p38a
in atherosclerosis, in the apolipoprotein E deficient (ApoE
2/2)
mouse model. Using the same model, we also studied the
macrophage-specific role of p38a in this disease. We generated
ApoE
2/2 mice lacking p38a in vascular endothelial cells or
macrophages and analyzed the development of atherosclerotic
plaques, after feeding a high cholesterol diet (HCD). Our results
show that specific ablation of p38a in macrophages or endothelial
cells did not affect the development of atherosclerotic plaques in
ApoE
2/2 mice, suggesting that p38a activity in these cell types
does not play a crucial role for the pathogenesis of atherosclerosis.
Results
P38a-deficiency inhibits oxLDL-induced adhesion
molecule and chemokine expression in primary
endothelial cells
Vascular endothelial cells have an important role in the
pathogenesis of atherosclerosis by expressing adhesion molecules
and chemokines that facilitate the recruitment of inflammatory
cells into the developing plaque. To address the role of p38a in
endothelial cells in atherosclerosis, we studied the contribution of
p38a activation in the expression of adhesion molecules and
chemokines by endothelial cells, upon stimulation with oxLDL.
For these experiments, we used primary mouse lung endothelial
cells (MLECs) isolated by Dynabead-mediated negative (LEAF)
and positive (CD102) selection from dissociated lung tissue from
p38a
FL/FL/ApoE
2/2 or ApoE
2/2 control mice. To delete p38a in
these cells, we used His-TAT-NLS-Cre (HTNC), a transducible
Cre recombinase that can be used efficiently to mediate
recombination of loxP flanked alleles in culture [21]. Purity of
endothelial cell cultures after Cre recombination was assessed by
flow cytometric analysis after staining with CD146 (Figure 1A).
Immunoblot analysis with p38a specific antibodies revealed a
strong reduction of p38a expression in HTNC-treated p38a
FL/FL/
ApoE
2/2 MLECs, indicating efficient ablation of p38a (Figure 1B,
middle panel). Furthermore, immunoblot with antibodies recog-
nizing phosphorylated p38 revealed that stimulation with 100 mg/
ml oxLDL induced strong p38 activation in control (ApoE
2/2)
cells, while p38a-deficient MLECs showed weak p38 activation.
As the phospho-p38 antibody used is not isoform-specific, the
weak p38 phosphorylation detected most likely corresponds to
phosphorylation of the residual p38a and also other p38 isoforms,
such as p38b, which is the other major p38 isoform expressed in
endothelial cells [22], (Figure 1B, top panel). We then assessed the
oxLDL-induced expression of vascular adhesion molecule 1
(VCAM1) and the chemokines IP-10, MCP-1 and Gro-KC,
known to be involved in the recruitment of monocytes into the
arterial intima. Quantitative real-time PCR (qRT-PCR) analysis
on RNA, isolated at different time points after oxLDL stimulation,
revealed induction in expression of VCAM1, IP-10, MCP-1 and
Gro-KC in control MLECs, which was strongly reduced in
MLECs lacking p38a (Figure 1C).
Endothelial cell p38a deficiency does not affect
atherosclerosis development in ApoE
2/2 mice
The results of the above described experiments suggested that
p38a activity in endothelial cells might play an important role for
the development of atherosclerotic plaques and encouraged us to
study in vivo the effect of endothelial cell specific p38a ablation, in
the development of atherosclerosis. For this purpose we used Cre-
loxP-mediated conditional targeting of p38a in ApoE-deficient
mice, which spontaneously develop atherosclerotic plaques due to
elevated blood cholesterol levels, a pathology that is further
aggravated upon feeding with a HCD. Thus, we crossed mice
carrying loxP-flanked p38a alleles with Tie2ER
T2Cre transgenics,
which mediate tamoxifen-inducible Cre recombination specifically
in endothelial cells [23] and subsequently with ApoE
2/2 mice. To
induce Cre-mediated excision of the loxP-flanked p38a allele in
endothelialcells,wefedgroupsof6–8 weekoldp38a
EC-KO/ApoE
2/2
and their p38a
FL/FL/ApoE
2/2 littermates that did not carry the
Tie2ER
T2Cre transgene with a diet containing tamoxifen (400 mg/
kg tamoxifen citrate, 5% sucrose in phytoestrogen-free chow) for 5
consecutive weeks [24]. The mice were subsequently placed on
HCD for 10 weeks to facilitate the development of atherosclerotic
plaques. To assess the efficiency of p38a ablation, we measured
p38a expression in primary endothelial cells isolated by CD146-
mediated magnetic cell sorting (MACS) from the lungs of mice, at
the end of the HCD feeding. Flow cytometric analysis of cell
fractionscollectedduringMACSsorting showedefficientseparation
of CD146
+ and CD146
2 fractions (Figure S1). Immunoblot analysis
of protein lysates from whole lung, CD146
+ and CD146
2 cell
fractionsshowedefficientablationofp38a inendothelialcellisolates
from p38a
EC-KO/ApoE
2/2 mice, indicating that tamoxifen-treat-
ment induced efficient ablation of p38a in the vascular endothelium
that persisted during the period of HCD feeding (Figure 2A).
Measurement of bodyweight and cholesterol levels beforeand after
the HCD treatment revealed no differences between p38a
EC-KO/
ApoE
2/2 and their ApoE
2/2 littermate controls, which showed
similarly increased cholesterol levels and body weight after HCD
feeding (Figure S2A). After 10 weeks on HCD, mice were
sacrificed, and atherosclerotic lesion development was assessed
in the whole aorta by en face staining with Sudan IV (Figure 2B),
but also at the aortic sinus by histological analysis of consecutive
sections followed by cross-sectional plaque area quantification
(Figure 2C). This analysis did not reveal differences in lesion
size between p38a
EC-KO/ApoE
2/2 and their ApoE
2/2 littermates,
either in the whole aorta or at the aortic sinuses. To further
characterize the lesions, we assessed collagen and foam cell
content and necrotic core formation. Quantification of collagen
on sections stained with Masson Trichrome did not reveal
differences in collagen content in plaques from p38a
EC-KO/
ApoE
2/2 mice compared to ApoE
2/2 controls (Figure 3A). In
addition, staining with a MOMA2 antibody to detect macro-
phages showed a similar foam cell content in plaques from
p38a
EC-KO/ApoE
2/2 mice compared to ApoE
2/2 controls
(Figure 3B). Finally, quantification of necrotic core area in
sections from the aortic sinus did not reveal differences between
p38a
EC-KO/ApoE
2/2 and ApoE
2/2 controls (Figure 3C). Taken
together, our experiments showed that endothelial p38a
deficiency does not affect atherosclerotic plaque size or
composition in ApoE
2/2 mice. These results were surprising in
light of our in vitro findings, showing that p38a was essential for
oxLDL-induced expression of adhesion molecules and chemo-
kines that are important for monocyte recruitment in athero-
The Role of P38a MAPK in Atherosclerosis
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21055Figure 1. Attenuated monocyte recruitment molecule expression in p38a deficient endothelial cells, in vitro. (A) Flow cytometric
analysis of primary lung endothelial cells to check for purity of population, after treatment with HTNC for 16 hrs. Cells were stained with CD146 FITC,
specific for MLECs. Leukocytes isolated from blood were used as negative controls for CD146 staining (data not shown). (B) Immunoblotting for p38a
and total p-p38 on MLEC protein extracts. (C) Relative mRNA expression levels of adhesion molecule VCAM1 and chemokines IP-10, MCP-1 and Gro-
KC in MLECs. Cells were isolated from the lung of p38a
FL/FL/ApoE
2/2 and ApoE
2/2 mice, passaged twice and treated with HTNC for 16 hrs to induce
cre recombination. Data shown are representative of two separate experiments. Error bars represent SD.
doi:10.1371/journal.pone.0021055.g001
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cytokines, chemokines and adhesion molecules in aortic roots
from p38a
EC-KO/ApoE
2/2 and ApoE
2/2 control mice at the end
of the HCD treatment. These experiments did not show any
significant differences in cytokine, chemokine or adhesion
molecule expression between p38a
EC-KO/ApoE
2/2 and ApoE
2/
2 control mice (Figure 3D). Thus, our results show that
endothelial cell-specific ablation of p38a does not affect the
development of atherosclerosis in the ApoE
2/2 model of the
disease.
Macrophage-specific function of p38a in atherosclerosis
To study the macrophage-specific role of p38a in atheroscle-
rosis, we crossed p38a
FL/FL/ApoE
2/2 mice with LysMCre mice
expressing Cre recombinase in macrophages and neutrophils [25].
Southern blot and immunoblot analysis of DNA and protein
extracts from Bone Marrow- Derived Macrophage (BMDM)
extracts showed efficient ablation of p38a in macrophages of
p38a
MY-KO/ApoE
2/2 mice (Figure 4A and B middle panel,
respectively and figure S3A). LPS stimulation induced strong
p38 phosphorylation in ApoE
2/2 control cells, while low levels of
p38 phosphorylation were detected in p38a-deficient macrophages
(Figure 4B, top panel and S3B).
To address the potential role of macrophage p38a in
atherosclerosis, we placed groups of male and female p38
MY-KO/
ApoE
2/2 and their ApoE
2/2 littermates on HCD for 10 weeks,
starting from 6–8 weeks of age. Analysis of bodyweight and
cholesterol levels, before and after the HCD treatment, revealed
no differences between the two genotypes, which showed similarly
increased cholesterol levels and body weight after HCD feeding
(Figure S2B). After 10 weeks on HCD, mice were sacrificed, and
atherosclerotic lesion development was assessed in the whole aorta
by en face staining with Sudan IV (Figure 4C), but also at the aortic
sinuses (Figure 4D). This analysis did not reveal differences in
lesion size between p38a
MY-KO/ApoE
2/2 and their ApoE
2/2
littermates, either in the whole aorta or in the aortic sinuses.
Quantification of collagen content, foam cell formation and
necrotic area also did not reveal any differences between the two
genotypes (Figure 5A, B and C, respectively). Taken together, our
experiments showed that macrophage p38a deficiency did not
affect atherosclerotic plaque development in ApoE
2/2 mice as
assessed by quantification of lesion size, collagen and macrophage
content and necrotic core area. These findings are in contrast to
the results reported by Seimon and colleagues, who found
increased lesional necrosis and decreased collagen content in
atherosclerotic plaques from p38a
MY-KO/ApoE
2/2, compared to
ApoE
2/2 controls [8].
Lesional macrophages secrete a wide range of pro-inflammatory
and pro-atherosclerotic genes and p38a has been shown to
regulate the expression of many of these genes in this cell type
[18], [26], [20]. Thus, we measured the expression of a panel of
cytokines, chemokines and adhesion molecules on RNA isolated
from the aortic arch of p38a
MY-KO/ApoE
2/2 and ApoE
2/2
littermates after 10 week on HCD. QRT-PCR expression analysis
failed to reveal any considerable differences in the expression of
any of the genes tested (Figure 5D), suggesting that p38a
macrophage deficiency does not seem to significantly affect the
expression of several pro-inflammatory mediators in the aorta.
Previous studies using chemical p38 inhibitors suggested that
p38a activity in macrophages is required for oxLDL uptake and
foam cell formation [12]. To address the potential role of p38a in
oxLDL uptake we stimulated thioglycolate-elicited peritoneal
macrophages (PMs) from p38a
MY-KO/ApoE
2/2 and ApoE
2/2 mice
with 50 mg/ml oxLDL and measured uptake by flow cytometric
analysis (Figure S4A) and Oil Red O staining for lipids by
microscopy (Figure S4B). Contrary to the findings of Zhao et al.,
our results revealed that p38a deficiency did not affect the capacity
of macrophages to take up oxLDL.
In conclusion, the results from our in vivo and in vitro analysis did
not reveal differences in any of the examined parameters addressing
atherosclerotic plaque formation in p38a
MY-KO/ApoE
2/2 mice
compared to ApoE
2/2 controls, suggesting that p38a signaling in
macrophages does not play an important role in the development of
atherosclerosis in the ApoE deficient mouse model.
Discussion
Inflammation is now recognized as a critical pathogenic
component for the development and progression of atherosclerotic
plaques. Modified lipids act on resident vascular cells and also
infiltrating inflammatory cells to induce and sustain the constant
recruitment of blood monocytes into the arterial intima. Recruited
monocytes differentiate into lipid laden foam cells, which are
trapped and eventually die within the lesions. Inefficient clearance
of apoptotic foam cells gives rise to a necrotic core in advanced
lesions [5]. Thus, the mechanisms that control the recruitment,
differentiation, activation, death and clearance of macrophages in
atherosclerotic plaques are crucial for the development and
progression of atherosclerosis [3], [4].
Intracellular signaling pathways that are activated downstream
of innate and cytokine receptors and coordinate the expression of
adhesion molecules, chemokines and cytokines that control
inflammatory responses, are believed to play an important role
in atherosclerosis. The p38 MAPK pathway is activated by a
multitude of inflammatory and danger signals and coordinates
cellular responses including survival, differentiation, proliferation,
and the activation of pro-inflammatory gene expression programs
[27]. These properties strongly suggested that p38 signaling must
be implicated in the pathogenesis of atherosclerosis. In addition,
systemic deficiency of MK2, a downstream effector of p38
signaling, reduced the severity of atherosclerosis in Ldlr
2/2 mice
[28], suggesting that p38 signaling indeed is important for this
disease. We therefore decided to address in vivo the potential role of
p38 in the development of atherosclerotic plaques. Since systemic
p38a deficiency leads to embryonic lethality, we used conditional
targeting of p38a in the ApoE
2/2 model of the disease. We chose
to target p38a in endothelial cells and macrophages, two cell types
with important functions in atherosclerosis.
Endothelial cell activation and expression of pro-inflammatory
mediators and adhesion molecules plays a crucial role in the
development of atherosclerosis by recruiting monocytes into the
Figure 2. Comparable atherosclerotic plaque formation in p38a
EC-KO/ApoE
2/2 and ApoE
2/2 mice after 10 weeks of HCD. (A) Analysis of
deletion efficiency by immunoblotting in p38a
EC-KO/ApoE
2/2 and their ApoE
2/2 littermates after 5 weeks of tamoxifen diet and 10 weeks of HCD, by
MACS sorting of MLECs with CD146. CD146
+=MLECs, CD146
2=other cells. P38
EC-KO/Apo
2/2 females, n=9; ApoE
2/2 females, n=6. (B) Quantification
of lesion area on whole aorta from female p38a
EC-KO/ApoE
2/2 and ApoE
2/2 mice. En face Sudan IV staining of plaques. P38a
EC-KO/ApoE
2/2 females,
n=14;ApoE
2/2 females, n=13.Scale bar, 2 mm. (C)Quantificationof lesion area onatherosclerotic plaquesat the aortic sinusof p38a
EC-KO/ApoE
2/2 and
ApoE
2/2 mice. Plaques are marked by arrows on aortal cross sections at the height of the aortic sinus. P38a
EC-KO/ApoE
2/2 females, n=14; ApoE
2/2
females, n=13; p38a
EC-KO/ApoE
2/2 males, n=14; ApoE
2/2 males, n=15. Scale bar, 0.2 mm.
doi:10.1371/journal.pone.0021055.g002
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activate intracellular signaling pathways that control endothelial
cell responses important for atherosclerosis. P38a has been
implicated in this process through regulating migration and
proliferation of endothelial cells [14], [15], cell permeability [16],
apoptosis [17], expression of adhesion molecules like VCAM1 [18]
and of various pro-inflammatory cytokines [10], [18]. Using p38a-
deficient primary endothelial cells, we could indeed show here that
p38a plays a crucial role in the expression of VCAM1 and the
chemokines MCP-1, IP-10 and Gro-KC upon oxLDL stimulation.
However, our in vivo experiments showed that endothelial cell-
specific ablation of p38a did not affect the development of
atherosclerosis in ApoE
2/2 mice, as assessed by measurement of
lesion size, macrophage and collagen content and necrotic core
area. In addition, endothelial p38a deficiency did not affect the
expression of a number of proinflammatory mediators known to
regulate atherosclerosis in aortic lesions from ApoE
2/2 mice fed
with HCD for 10 weeks. Considering our in vitro results and the
large amount of literature claiming an important role for p38a in
endothelial cells for the development of atherosclerosis, the finding
that endothelial p38a deficiency did not affect atherosclerosis
development in vivo is surprising.
Likewise, myeloid cell specific p38a deficiency did not have a
measurable effect in the development of atherosclerotic plaques in
ApoE
2/2 mice fed for 10 weeks with a HCD, as assessed by en face
staining of whole aortas and histological analysis of aortic root
sections. Moreover, quantification of plaque characteristics like
macrophage and collagen content and of necrotic core areas in
aortic root lesions also revealed no considerable differences between
p38a
MY-KO/ApoE
2/2 and ApoE
2/2 mice. Inflammatory gene expres-
sion analysis in aortic lesions also failed to reveal an effect of
macrophage p38a deficiency in the expression of mediators
controlling the development of atherosclerosis. Thus, our results
demonstrate that macrophage p38a deficiency did not affect the
development of atherosclerotic plaques in the ApoE
2/2mousemodel,
suggesting that macrophage p38a does not have an important role in
the pathogenesis of atherosclerosis. Seimon et al. also studied the role
of macrophage p38a in atherosclerosis using a similar experimental
system [8]. In agreement with our results, they showed that
macrophage p38a deficiency did not affect lesion size and
macrophage content in aortic root plaques. However, in contrast to
our findings and the findings from Jagaveluet al. with the downstream
p38 effector MK2 [28], they found that plaques in ApoE
2/2 mice
lacking p38a in macrophages showed increased necrotic areas,
attributed to a function of p38a in protecting macrophages from ER-
stress induced apoptosis. Since both studies were performed on mice
in C57Bl/6 genetic background and using the same high cholesterol
diet for a similar time period, currently, we cannot explain this
difference between our study and that of Seimon et al.
At this stage we cannot exclude that combined deficiency of p38a
in both macrophages and in endothelial cells might not affect
atherosclerosis development in vivo or that p38a might function in
other cell types such as smooth muscle cells to control atheroscle-
rotic lesion pathogenesis. However, our findings highlight the
potential complexity and redundancy in the processesregulating the
development of atherosclerotic plaques in vivo and suggest that
multiple mechanisms that are controlled by different signaling
cascades contribute to the pathogenesis of atherosclerosis.
Taken together, our studies demonstrate that the macrophage and
endothelial specific inhibition of p38a signaling does not protect
against atherosclerosis. Without neglecting the fact that this molecule
could be an important player in other cell types involved in
atherosclerosis development (e.g. smooth muscle cells), these results
suggest that p38 inhibitors may not be an appropriate therapeutic
strategy for the prevention and treatment of atherosclerosis.
Materials and Methods
Ethics statement
All animal procedures were approved by the governmental
ethics committee and were performed in compliance with the
licenses No. /50.203.2-K13, 12/06/ of July, 7 2006 (elongated
May, 12 2009) and /8.87-50.10.37.09.242/ of October, 10 2009,
granted by the State Office for Nature, Environment and
Consumer Protection of North Rhine-Westphalia (Landesamt
fu ¨r Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen),
Germany. The investigation conforms to the ‘Guide for the Care
and Use of Laboratory Animals’ published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996).
Mice and diet
Conditional male and female p38a
FL/FL [29] mice were crossed
with LysMCre [25] and Tie2ER
T2Cre [23] transgenic mice, to
generate myeloid and endothelial cell-specific knockouts, respec-
tively. These mice were then crossed with ApoE
2/2 mice [30], a
widely accepted mouse model of atherosclerosis. For induction of
Cre activity, mice carrying the Tie2ER
T2Cre transgene and their
Cre-negative littermates were fed a tamoxifen-containing diet
(400 mg/kg tamoxifen citrate, 5% sucrose, 95% Teklad Global,
16% Rodent Diet) from Harland Teklad, as previously described
[7], for 5 weeks. Atherosclerosis development was accelerated, in
both macrophage- and endothelial-specific p38a knockout mice,
by placing them on a high-cholesterol diet (HCD) from Harlan
Teklad (Teklad Adjusted Calories 88137; 21% fat (WT/WT),
0.15% cholesterol (WT/WT) and 19.5% casein (WT/WT); no
sodium cholate) for 10 weeks, starting at 6–8 weeks, or after
tamoxifen feeding, respectively. All mice used in the experiments
described here were backcrossed into the C57BL/6 genetic
background for at least five generations.
Genotyping and blood analysis
Primers for the wild-type, floxed or deleted p38a alleles were:
59-CTACAGAATGCACCTCGGATG-39; 59-AGAAGGCTGGATTTG-
CACAAG-39; 59-CCAGCACTTGGAAGGCTATTC-39 and for the
wild-type or ApoE deleted alleles were: 59-GCCTAGCCGAGGGA-
GAGCCG-39; 59-TGTGACTTGGGAGCTCTGCAGC-39; 59-GCCGC-
CCCGACTGCATCT-39. Primers for the LysMCre transgene were:
59-CTTGGGCTGCCAGAATTTCTC-39; 59-TTACAGTCGGCCAG-
GCTGAC-39; 59-CCCAGAAATGCCAGATTACG-39 and for the
Tie2ER
T2Cre transgene were: 59-GTCCAATTTACTGACCGTA-
CAC-39; 59-CTGTCACTTGGTCGTGGCAGC-39.
Figure 3. Similar plaque characteristics, cytokine, chemokine and adhesion molecule expression in p38a
EC-KO/ApoE
2/2 and ApoE
2/2
mice. Staining and quantification at the aortic sinus of p38a
EC–KO/ApoE
2/2 mice for: (A) Collagen content, Masson Trichrome staining (blue fibres,
indicated by arrows) (B) Foam cell content, MOMA2 staining (red, indicated by arrows). (C) Necrotic core area, clear areas in lesions that did not stain
for toluidine blue (nec=necrosis). (D) Relative mRNA levels of adhesion molecules, chemokines and pro-inflammatory cytokines (from left to right) of
aortal arches from p38a
EC-KO/ApoE
2/2 and ApoE
2/2 mice after 10 weeks on HCD. P38a
EC-KO/ApoE
2/2 females, n=9; ApoE
2/2 females, n=6. Scale bar
50 mm. Error bars represent SD.
doi:10.1371/journal.pone.0021055.g003
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overnight fasting using the PAD-CHOL reagent (Roche) and reading
absorbance at 500 nm, according to manufacturer’s instructions.
Atherosclerotic lesion analysis
Consecutive 7 mm sections of the heart, at the level of the
atrioventricular valves, were collected and stained with toluidine
blue for morphometric analysis and atherosclerosis quantification,
as previously described [7]. Toluidine stained sections were also
used for the quantification of the necrotic core area, which was
defined as a clear area that was toluidine free [8]. En face analysis
of atherosclerotic lesions was performed by Sudan IV staining (red)
of whole aortas, as described previously [7]. Plaque areas, in both
the atrioventricular valves and the whole aortas, but also the
necrotic core area, were quantified using Adobe Photoshop.
Histology and immunostainings
For MOMA2 (anti-mouse macrophages/monocytes
MCA519GT, Serotec) immunostainings, frozen sections of the
aortic root were fixed in ice-cold acetone, blocked in 4% FCS with
Avidin D solution (Avidin/Biotin Blocking Kit; Vector Laborato-
ries) for 30 min and incubated with primary antibody (MOMA2,
rat, 1:1000) for 60 min in 4% FCS with Biotin (Avidin/Biotin
Blocking Kit; Vector Laboratories). Sections were then incubated
with biotin-conjugated rabbit anti-rat/biotinylated antibody
(E0468, 1:100, DakoCytomation) in 4%FCS/2% NMS for
60 min, incubated in Avidin/Biotin solution in PBS (Vectastain
ABC Kit, Vector Laboratories) and color was developed with AEC
substrate (Vector Laboratories). The sections were then counter-
stained with haematoxylin and mounted with Entellon (MERCK).
Immunostaining for collagen on frozen sections of the aortic
root were performed by using the Masson Trichrome staining kit,
which stains keratin and muscle fibers red, collagen green or blue,
cytoplasm light red or pink, and cell nuclei dark brown to black
(Sigma Aldrich), according to the manufacturer’s instructions.
Macrophage isolation
Bone marrow-derived macrophages (BMDM) were obtained
according to standard procedures [7]. In brief, bone marrow cells
isolated from the femurs of mice, were subjected to red blood cell
(RBC) lysis and plated on 10 cm bacterial Petri dishes (Greiner) in
RPMI Glutamax (Invitrogen) supplemented with 10% FCS,
penicillin/streptomycin and 20% L929 conditioned medium.
The cells were cultured for 8 days and starved in RPMI without
FCS for 3 hrs, before experiments were performed.
Thioglycolate-elicited peritoneal macrophages (PM) were isolat-
ed as described elsewhere [31]. After RBC lysis, cells were washed
extensively using ice-cold PBS and seeded on 6-well bacterial plates
(Greiner) in RPMI Glutamax medium supplemented with 10%
FCS. After 2 hrs, non-adherent cells were washed out with PBS and
cells were starved for 48 hrs before experiments were performed.
Mouse lung endothelial cell isolation (MLECs)
Lungs were dissected from PBS perfused mice, sterilized in 75%
ethanol and placed in fresh DMEM (Gibco). Lungs were then cut
into small pieces and incubated in 0.2% collagenase in DPBS+
CaCl2 (Gibco) for 1 hr at 37uC. Remaining tissue was broken down
through a 19G needle and strained through a 70 mM cell strainer.
The cell suspension was then centrifuged 1500 rpm/5 min and the
pellet was resuspended in endothelial cell medium (DMEM low
glucose: Ham’s F-12 1:1, 20% FCS, 50 mg/ml endothelial mitogen,
25 mg/ml heparin, 100 U/ml penicillin/streptomycin and 2 mM
glutamine) and plated on a previously coated (0.1% gelatin, 10 mg/
ml human fibronectin, 30 mg/ml bovine collagen type I) T75 flask.
Endothelial cells were enriched by negative (LEAF rat anti-mouse
CD16/32,1:2000dilution,Biolegend)andpositive(CD102ratanti-
mouse, 1.5:2000 dilution, BD Biosciences) selection using Dyna-
beads (sheep anti-rat IgG, Invitrogen) duringpassages 1–2. Purity of
the cell population was assessed by CD146 FITC (Miltenyi Biotec)
staining and flow cytometric analysis.
At passage 8, MLECs were treated with His-TAT-NLS-Cre
(HTNC) to induce recombination of p38a loxP flanked alleles [21],
overnight (16 hrs), in medium containing DMEM (low glucose):
RPMI: PBS (1:1:2 ratio) and 100 U/ml penicillin/streptomycin.
The HTNC medium was then replaced with endothelial cell
medium. The cells were allowed to reach confluence and passaged
1–2 times more before experiments were performed.
MACS sorting of MLECS
MLECS were isolated from female p38a
EC-KO/ApoE
2/2 and
ApoE
2/2 littermates after a 10 week HCD. Collagenase
dissociated lungs were passed through a 19G needle to form a
cell suspension, which was subsequently passed through a 100 mm,
a7 0mm and a 40 mm cell strainer. After washing twice with PBS,
debris removal and cell enrichment of the remaining cell
suspension was achieved by mixing with a 30% Histodenz solution
(Sigma-Aldrich) and centrifuging 15006g/2 mins to form a
gradient. Low-density cells at the interface were harvested and
washed twice in degassed MACS buffer (PBS pH 7.2, 0.5% BSA
and 2 mM EDTA). Cells were resuspended in MACS buffer
(90 ml/10
7 cells) and labeled with Anti-LSEC magnetic MicroBe-
ads (beads coupled to the mouse endothelial cell marker CD146,
Miltenyi Biotec) by adding 10 ml beads/10
7 cells and incubating
15 mins/4uC. After washing, the cells were resuspended in 500 ml
buffer/10
8 cells. Magnetic separation of the cells was performed
on a MACS column (MS, Miltenyi Biotec), where CD146 positive
endothelial cells were retained on the column and eluted only
upon removal from the magnetic field. CD146 sorting of lung
endothelial cells was confirmed through flow cytometry (FITC),
after staining with a CD146-FITC conjugated antibody (Miltenyi
Biotec), according to manufacturer’s instructions. Cells obtained
from MACS sorting were used to confirm efficient ablation of
p38a in endothelial cells, by immunoblotting.
Oxidized low-density lipoprotein stimulation (OxLDL)
CuSO4 oxidation of human LDL (AppliChem) was performed
according to standard protocols [6]. DiI-labeling was achieved by
further incubation of the oxidized products with 300 mg DiI
reagent/mg LDL (Molecular Probes) for 18 hrs at 37uC, before
dialysis.
Figure 4. P38a ablation in macrophages does not affect atherosclerosis development. (A) Southern blotting on protein extracts from
p38a
MY-KO/ApoE
2/2 and ApoE
2/2 BMDMs to analyse p38a deletion efficiency in macrophages. P38a
MY-KO/ApoE
2/2 mice, n=3; ApoE
2/2, n=3. (B) LPS
(1 mg/ml, Sigma) stimulation and immunoblotting of protein extracts from p38a
MY-KO/ApoE
2/2 and ApoE
2/2 BMDMs. (C) Quantification of lesion size
on whole aorta from male p38a
MY-KO/ApoE
2/2 and ApoE
2/2 mice. En face Sudan IV staining of lesions. P38a
MY-KO/ApoE
2/2 males, n=9; ApoE
2/2 males,
n=9. Scale bar 2 mm. (D) Quantification of lesion area of atherosclerotic plaques at the aortic sinus of p38a
MY-KO/ApoE
2/2 and ApoE
2/2 mice. Plaques
are marked by arrows on aortal cross sections at the height of the aortic sinus. P38a
MY-KO/ApoE
2/2 males, n=9; ApoE
2/2 males, n=15; p38a
MY-KO/
ApoE
2/2 females, n=8; ApoE
2/2, n=9. Scale bar, 0.2 mm.
doi:10.1371/journal.pone.0021055.g004
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PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e21055OxLDL stimulation of PMs was performed as previously
described, using 50 mg/ml DiI-labeled oxLDL [31]. Foam cell
formation was visualized by staining overnight with Oil-red O
(red) and counterstaining with hematoxylin. Uptake of oxLDL was
quantified by flow cytometry (PE).
For MLECs, before oxLDL stimulation, cells were starved
overnight unless otherwise indicated and 100 mg/ml oxLDL was
added to the medium for indicated timepoints.
Immunoblot analysis
Immunoblot analysis was performed as described elsewhere
[29]. Membranes were probed with specific antibodies against a-
tubulin (Sigma-Aldrich, T6074), p38a (Cell signaling, #9218), and
p-p38 (Cell Signaling, #9211). Horseradish peroxidase-conjugated
anti-rabbit and anti-mouse secondary antibodies were used
(Amersham). Band volumetric analysis on western blots was
performed using Radames software (Kindly provided by Dr.
Hanns-Eugen Sto ¨ffler). P38a and total phosphorylated p38 were
calculated by dividing the abundance of each protein by tubulin
abundance (Figure S4).
Southern blot analysis
Genomic DNA isolated from BMDM was digested overnight at
37uCi na5 0ml BamHI reaction (16BamHI restriction buffer,
1 mM spermidine, 1 mM DTT, 100 mg/ml BSA, 50 mg/ml
RNase A and 50 U BamHI enzyme/reaction). The DNA
fragments were separated on a 0.8% agarose gel that was
denatured by soaking for 45 mins in denaturing solution (0.4 M
NaOH, 0.7% NaCl), and transferred overnight by capillary flow
onto the surface of a charged nylon membrane (Hybond XL,
Amerscham). The membrane was then soaked in neutralization
solution (0.5 M Tris-HCl, 1.5 M NaCl), incubated at 70uC for
1 hr and prehybridized in hybridization buffer (1 M NaCl,
50 mM Tris-HCl pH 7.5, 10% dextransulphate, 1% SDS,
250 mg/ml Salmon Sperm DNA) at 65u for 3 hrs. DNA probes
labeled by random priming with 32a-dGTP were added to the
hybridization buffer and allowed to hybridize to the membrane
overnight at 65uC. The membrane was then washed and exposed
to autoradiographic film. Probe sequences used for the detection of
p38a wild-type, floxed and deleted DNA fragments are available
upon request.
Quantitative real-time PCR
RNAwasisolatedfrom aortas,macrophages and endothelial cells
using Trizol-reagent (Invitrogen) and RNeasy columns (QIAGEN),
as previously described [7]. Briefly, RNA (1 mg) was used for reverse
transcription with SuperScript III reverse transcriptase (Invitrogen).
The reaction was topped up to 200 ml with water, and 2 ml were
used for quantitative real-time PCR (qRT-PCR) reaction with the
TaqMan qPCR Kit from Eurogentec. Standardization was
performed with GAPDH (TaqMan). Taqman probes used for the
quantification of MCP-1,VCAM1, IP-10, Gro-KC, RANTES,
MIP-1a, Fractalkine, MIP-1b, MCP-3, IL-1b, IL-18, TNF, IL-6
and IL-10, were obtained from Applied Biosystems.
Statistical analysis
All statistical analyses were performed using the Prism software
(GraphPad Software Inc., San Diego, CA), and Excel. Statistical
significance between experimental groups was assessed using an
unpaired two sample Student’s t test. Data are expressed as means
6SD. A p value of less than 0.05 is considered statistically
significant.
Supporting Information
Figure S1 MACS sorting of MLECS. Flow cytometric
analysis of fractions collected during MACS sorting of lung
endothelial cells from mice, after 10 weeks of HCD, showed
efficient separation of CD146 positive and negative fractions.
(TIF)
Figure S2 Cholesterol and bodyweight of mice on HCD.
Cholesterol (mg/dl) (top) and bodyweight (gr) (bottom) levels of (A)
male and female p38
EC-KO/ApoE
2/2 and ApoE
2/2 mice (p38a
EC-KO/
ApoE
2/2 males, n=14; ApoE
2/2 males, n=15; p38a
EC-KO/ApoE
2/2
females, n=14; ApoE
2/2 females, n=13) and (B) male and female
p38a
MY-KO/ApoE
2/2 and ApoE
2/2 mice (p38a
MY-KO/ApoE
2/2 males,
n=9; ApoE
2/2 males, n=15; p38a
MY-KO/ApoE
2/2 females, n=8;
ApoE
2/2 females, n=9), before and after 10 weeks of a HCD. Error
bars represent SD.
(TIF)
Figure S3 Quantification of p38a expression and p38
phosphorylation in MLECs. The expression of p38a and the
levels of phosphorylated total p38 in figure 4B were quantified by
performing volumetric analysis of the bands identified by
immunoblot with p38a and p-p38 specific antibodies.
(TIF)
Figure S4 Similar oxLDL uptake in p38a
MY-KO/ApoE
2/2
and ApoE
2/2 macrophages, in vitro. (A) Quantification by
flow cytometry of oxLDL uptake by thioglycolate-elicited PMs,
after 50 mg/ml DiI-oxLDL stimulation for 2.5 hrs. (B) Staining of
oxLDL stimulated macrophages with Oil red O (lipid staining).
Foam cells, defined as cells with $10 lipid droplets, are indicated
with arrows. ApoE
2/2 mice, n=3; p38a
MY-KO/ApoE
2/2,n=3 .
(TIF)
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Figure 5. Similar plaque characteristics, cytokine, chemokine and adhesion molecule expression in p38a
MY-KO/ApoE
2/2 and ApoE
2/2
mice. Staining and quantification at the aortic sinus of p38a
MY-KO/ApoE
2/2 and ApoE
2/2 mice for: (A) Collagen content, Masson Trichrome staining
(blue fibres, indicated by arrows), (B) Foam cell content, MOMA2 staining (red, indicated by arrows), (C) Necrotic core area, clear areas in lesions that
did not stain for toluidine blue (nec=necrosis). (D) Relative mRNA levels of adhesion molecules, pro-inflammatory cytokines and chemokines (left to
right) of aortal arches from p38a
MY-KO/ApoE
2/2 and ApoE
2/2 mice after 10 weeks on HCD. P38a
MY-KO/ApoE
2/2 females, n=8; ApoE
2/2 females, n=9.
Scale bar 50 mm. Error bars represent SD.
doi:10.1371/journal.pone.0021055.g005
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